DCGI nod to Phase-1 human trials of 'antisera' with potential to treat COVID-19
- The '
antisera' has been developed by the Indian Council of Medical Research (ICMR) in collaboration with a Hyderabad-based bio-pharmaceutical firm.
- The pre-print version of the study regarding the development of the equine antisera has been posted on the Research Square platform.
The 'antisera' has been developed by the Indian Council of Medical Research (ICMR) in collaboration with a Hyderabad-based bio-pharmaceutical firm.
"With Biological E Limited we have developed an horse 'antisera' and we have just got clearance for conducting clinical trials for that," ICMR Director General Dr Balram Bhargava said at press briefing on Tuesday.
AdvertisementThe 'antisera' is yet to undergo human clinical trials to establish safety and efficacy.
Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fight specific infections.
"The ICMR and Biological E Limited,
The pre-print version of the study regarding the development of the equine antisera has been posted on the Research Square platform.
"The study provides evidence of the potential of generating highly purified F(ab')2 from equines against SARS-CoV-2 that can demonstrate consistent and high neutralisation activity," the study paper said.
"Further, in-vivo testing for efficacy of this indigenously developed, cost effective product will pave the way to clinical evaluation. Additionally, being a donor independent method, this may prove as an efficient alternative to convalescent plasma for treatment of COVID-19 patients," it said.
AdvertisementEarlier such measures were used for controlling several viral and bacterial infections.
"Although, plasma recovered from patients experiencing COVID-19 could serve similar purpose, the profile of antibodies, their efficacy and concentration keep varying from one patient to another and therefore, make it an unreliable clinical tool for patient management," the ICMR had said in a tweet.
"Standardisation achievable through equine sera based treatment modality thus stands out as yet another remarkable public health initiative supported by ICMR in the time of COVID-19," it said.
AdvertisementAs part of the study, 10 healthy horses were immunised with inactivated SARS-CoV-2 and after 21 days of immunisation, plasma samples were tested.
The results of the plasma samples indicated presence of SARS-CoV-2 specific IgG antibodies as detected in ELISA with neutralising capacity.
Samsung, Foxconn and Pegatron among 16 companies to get government nod to boost mobile manufacturing in India
Apple just announced an event on October 13 where it will likely unveil the iPhone 12
- Air conditioner and cooling brand Voltas India eyes double digit growth this summer
- Gautam Adani and Mukesh Ambani cumulatively lost nearly $7 billion as the markets plunged
- Dr. Reddy’s, TCS, Bandhan Bank and other stocks to watch out for on April 13
- Sushil Chandra appointed as Chief Election Commissioner with effect from April 13
- TCS has broken many records in the last three months — but that isn't good enough for the market